ImmuCell Corporation (NASDAQ:ICCC) Short Interest Up 147.1% in December

ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 15,418 shares, a growth of 147.1% from the November 30th total of 6,239 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average trading volume of 18,731 shares, the days-to-cover ratio is presently 0.8 days. Based on an average trading volume of 18,731 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.2% of the shares of the company are short sold.Wall Street Analyst Weigh InSeparately, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of ImmuCell in a report on Monday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, ImmuCell has an average rating of "Sell".Check Out Our Latest Stock Analysis on ICCCImmuCell Price PerformanceShares of ICCC traded up $0.32 during mid-day trading on Friday, reaching $6.12. The stock had a trading volume of 336,206 shares, compared to its average volume of 20,020. The business has a fifty day moving average of $5.69 and a 200 day moving average of $6.15. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.76 and a current ratio of 4.21. The firm has a market cap of $55.39 million, a price-to-earnings ratio of 23.54 and a beta of 0.20. ImmuCell has a 12 month low of $4.28 and a 12 month high of $7.60. ImmuCell (NASDAQ:ICCC - Get Free Report) last released its earnings results on Thursday, November 13th. The biotechnology company reported ($0.02) earnings per share for the quarter. ImmuCell had a net margin of 8.37% and a return on equity of 8.00%. The firm had revenue of $5.51 million for the quarter. Institutional Trading of ImmuCellAn institutional investor recently raised its position in ImmuCell stock. Geode Capital Management LLC increased its holdings in ImmuCell Corporation (NASDAQ:ICCC - Free Report) by 4.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,852 shares of the biotechnology company's stock after purchasing an additional 2,907 shares during the period. Geode Capital Management LLC owned 0.79% of ImmuCell worth $500,000 as of its most recent SEC filing. Institutional investors own 13.47% of the company's stock. About ImmuCell (Get Free Report)ImmuCell Corporation NASDAQ: ICCC is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics. The company's flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.Read MoreFive stocks we like better than ImmuCellDo you know what Amazon is planning for January 1?Shots officially fired…Washington prepares for warYour “birthright claim” just got activatedWall Street Stockpicker Names #1 Stock of 2026This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in ImmuCell Right Now?Before you consider ImmuCell, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.While ImmuCell currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here